$349 Million is the total value of GREAT POINT PARTNERS LLC's 39 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 42.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $30,277,000 | +32.6% | 2,705,758 | -0.9% | 8.67% | +5.8% |
| EXEL | Sell | EXELIXIS INC | $24,992,000 | +60.4% | 3,200,000 | -17.9% | 7.16% | +28.0% |
| TTPH | Sell | TETRAPHASE PHARMACEUTICALS I | $9,888,000 | -41.5% | 2,299,529 | -37.1% | 2.83% | -53.4% |
| XNCR | Sell | XENCOR INC | $8,546,000 | +20.5% | 450,000 | -14.9% | 2.45% | -3.9% |
| ADHD | Sell | ALCOBRA LTD | $6,351,000 | -17.0% | 1,414,573 | -30.0% | 1.82% | -33.8% |
| RPTP | Sell | RAPTOR PHARMACEUTICAL CORP | $5,254,000 | -15.2% | 978,350 | -27.3% | 1.50% | -32.3% |
| SNSS | Sell | SUNESIS PHARMACEUTICALS INC | $4,477,000 | +0.5% | 8,173,937 | -0.9% | 1.28% | -19.8% |
| CLBS | Sell | CALADRIUS BIOSCIENCES INC | $900,000 | -29.9% | 1,525,244 | -10.8% | 0.26% | -43.9% |
| VCEL | Sell | VERICEL CORP | $570,000 | -95.4% | 253,502 | -88.0% | 0.16% | -96.3% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $407,000 | -91.2% | 29,266 | -90.4% | 0.12% | -93.0% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $112,000 | -65.9% | 50,000 | -68.3% | 0.03% | -72.9% |
| LIFE | Exit | ATYR PHARMA INC | $0 | – | -49,906 | -100.0% | -0.07% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -29,300 | -100.0% | -0.22% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.37% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -1.00% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -1,300,000 | -100.0% | -2.38% | – |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -1,295,416 | -100.0% | -2.40% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS INput | $0 | – | -100,000 | -100.0% | -4.61% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -575,000 | -100.0% | -8.38% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.